What are the uses of Cagrilintide?

Weight management (investigational). Appetite and satiety control. Combination therapy with GLP-1 agonists

Weight Loss & MetabolicResearch Chemical

Cagrilintide

Also known as: AM833

Long-acting amylin analog paired with semaglutide (CagriSema) as a next-generation weight-loss combination.

Subcutaneous injection

Weight Loss & Metabolic

Cagrilintide

Subcutaneous injectionResearch Chemical

Investigational drug, not approved. Research/clinical-trial use only.

Overview

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for weight management. It is most notable as the amylin half of CagriSema, an investigational combination with semaglutide that has shown strong weight-loss results.

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk for weight management. Amylin is a hormone co-released with insulin that promotes fullness and slows how fast the stomach empties. By activating amylin and calcitonin receptors, cagrilintide reduces appetite and food intake through a mechanism that is complementary to — not the same as — GLP-1 drugs.

Its real fame comes from being the amylin half of CagriSema, an investigational once-weekly combination with semaglutide. The idea is that hitting two distinct satiety pathways at once produces greater weight loss than either alone. Phase III REDEFINE trials have shown substantial weight loss, though results have been intensely scrutinized against sky-high expectations. Cagrilintide is investigational and not yet approved.

Mechanism of Action

Activates amylin and calcitonin receptors to slow gastric emptying, increase satiety, and reduce food intake — complementary to GLP-1 receptor agonism.

Use Cases

✓Weight management (investigational)
✓Appetite and satiety control
✓Combination therapy with GLP-1 agonists

Research Summary

Phase II data for cagrilintide alone and Phase III REDEFINE trials for CagriSema (with semaglutide) show substantial weight loss, though CagriSema results have been closely scrutinized against expectations. Not yet approved.

Explain It Like I'm 5 Years Old

Your body has more than one hormone that tells your brain you are full. GLP-1 medicines use one of those signals. Cagrilintide uses a different one called amylin. The big idea is to press two fullness buttons at the same time — cagrilintide plus semaglutide — so people feel satisfied on less food and lose more weight than with one button alone.

How the Gym Bros Are Using It

More of a weight-loss and metabolic-health story than a gym story, but it matters because it is the other half of CagriSema — the combo everyone in the GLP-1 world is watching. The appeal is a second, non-GLP-1 fullness pathway stacked on top of semaglutide for bigger appetite control on a cut. It is investigational, so this is a watch-the-trials situation rather than something to run.